Document type

Article

Version

Published version

Publication date

Publication license

cc by-nc-nd (c) Candeloro, Matteo et al, 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/201093

Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis

Journal Title

Director/Tutor

Additional contribution

Journal ISSN

Volume Title

Abstract

Robust evidence on the optimal management of splanchnic vein thrombosis (SVT) is lacking. We conducted an individual-patient meta-analysis to evaluate the effectiveness and safety of anticoagulation for SVT. Medline, Embase, and clincaltrials.gov were searched up to June 2021 for prospective cohorts or randomized clinical trials including patients with SVT. Data from individual datasets were merged, and any discrepancy with published data was resolved by contacting study authors. Three studies of a total of 1635 patients were included. Eighty-five percent of patients received anticoagulation for a median duration of 316 days (range, 1-730 days). Overall, incidence rates for recurrent venous thromboembolism (VTE), major bleeding, and mortality were 5.3 per 100 patient-years (p-y; 95% confidence interval [CI], 5.1-5.5), 4.4 per 100 p-y (95% CI, 4.2-4.6), and 13.0 per 100 p-y (95% CI, 12.4-13.6), respectively. The incidence rates of all outcomes were lower during anticoagulation and higher after treatment discontinuation or when anticoagulation was not administered. In multivariable analysis, anticoagulant treatment appeared to be associated with a lower risk of recurrent VTE (hazard ratio [HR], 0.42; 95% CI, 0.27-0.64), major bleeding (HR, 0.47; 95% CI, 0.30-0.74), and mortality (HR, 0.23; 95% CI, 0.17-0.31). Results were consistent in patients with cirrhosis, solid cancers, myeloproliferative neoplasms, unprovoked SVT, and SVT associated with transient or persistent nonmalignant risk factors. In patients with SVT, the risk of recurrent VTE and major bleeding is substantial. Anticoagulant treatment is associated with reduced risk of both outcomes. © 2022 by The American Society of Hematology.

Citation

Citation

CANDELORO, Matteo, et al. Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Advances. 2022. Vol. 6, num. 15, pags. 4516-4523. ISSN 2473-9537. [consulted: 7 of October of 2026]. Available at: https://hdl.handle.net/2445/201093

Export metadata

JSON - METS

Share record